Jason Rhodes joins Atlas Venture investing team

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Jason Rhodes joins Atlas Venture investing team

Jason Rhodes, who recently exited his position as president of Epizyme ($EPZM), is making the hop to Atlas Venture, the well-known early-stage VC group based in Cambridge, MA. Rhodes joined Epizyme in 2010 through its $196 million IPO and before that had served as VP of business development at Alnylam ($ALNY). Release

Atlas Venture
Jason Rhodes joined the investing team.

Biotech

> NewLink Genetics ($NLNK) has appointed Jack Henneman as executive vice president and chief financial officer. Release

> Bio-Rad Laboratories ($BIO) has appointed John Goetz as chief operating officer. Release

> Dr. Jan Brinkman and Alan Hoberman have joined Boston Therapeutics' ($BTHE) board of directors. Release

> Susheel Surpal has stepped down as chief financial officer of Ipsen ($IPN). Release

> Relmada Therapeutics ($RLMD) has appointed Julie Chen as its director of finance and operations. Release

> Mast Therapeutics ($MSTX) has appointed Dr. Edwin Parsley as its chief medical officer and senior vice president. Release

> Brian McLellan was promoted to president of Astellas Pharma Technologies in the Americas region. Release

> Neurocrine Biosciences ($NBIX) has named Malcolm Lloyd-Smith as chief regulatory officer. Release

> Agile Therapeutics ($AGRX) has appointed Dr. James Tursi to its board of directors. Release

> CytoDyn ($CYDY) has appointed Carl Dockery to its board of directors. Release

> IntelGenx ($IGXT) has appointed Horst Zerbe as president and chief executive officer. Release

> BBB Therapeutics (formerly to-BBB) brought on Dr. Ferdinand Massari and Pericles Calias as chief medical officer and chief scientific officer, respectively. Release

> Leidos Biomedical Research named James Bahel its VP of business development. Release

> Protalix Biotherapeutics appointed Moshe Manor as its president and CEO. Release

> David Ricketts joined LINK as the company's new CEO. Release

> NeoGenomics ($NEO) brought on Robert Shovlin as its chief operating officer. Release

> Agilis named Dr. James Darnell of Rockefeller University as a member of its scientific advisory board. Release

> Cambridge Major Laboratories appointed Marcel Schreuder Goedheijt as its general manager. Release

> Susan Boynton joined Arrowhead ($ARWR) as vice president of global regulatory affairs. Release

> Verona Pharma appointed Biresh Roy as CFO and a member of the board. Release

> Generex named Lakshmi Kotra as part of its Buccal Insulin Enhancement Project. Release

Dr. Hal Barron, president of R&D at Google's ($GOOG) Calico, has been appointed to the board of Juno Therapeutics. Release

> Stephen Aselage will take over as interim CEO, to replace Martin Shkreli, founder and CEO of Retrophin. Release

Pharma

> Zynerba Pharmaceuticals has appointed Armando Anido as chief executive officer and chairman of the board. Release

> Conatus Pharmaceuticals ($CNAT) has appointed David Hagerty as executive vice president of clinical development. Release

> Horizon Pharma's ($HZNP) commercial chief Todd Smith resigned from the position. Release

> Cerulean Pharma ($CERU) appointed Alejandra Carvajal as VP and general counsel. Release

> Inovio Pharmaceuticals ($INO) appointed Jennifer Laux as its vice president of commercial development. Release

> Accelovance brought on Dr. Joseph Purvis, former VP of oncology at Pfizer ($PFE), to the same position. Release

> Ritter Pharmaceuticals named Michael Step its CEO. Release

> Torbjörn Bjerke left Karolinska Development and the company appointed Klaus Wilgenbus as acting CEO. Release | Story

> Nimbus Discovery appointed Donald Nicholson as its CEO. Release

> Shameze Rampertab, vice president of finance and chief financial officer, has resigned from IntelliPharmaCeutics ($IPCI). Release

Vaccines

> Dr. Jon Andrus joined the Sabin Vaccine Institute as its executive vice president. Release

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.